NCT01600456

Brief Summary

The specific aims of this study are:

  1. 1.To compare the effectiveness of a cognitive behavioral therapy (prolonged exposure, PE) to that of PE and medication (sertraline).
  2. 2.To compare the durability of PE gains to that of PE and sertraline at 3, 6, and 9 months post-treatment.
  3. 3.To compare those who have chosen their treatment to those who have not in terms of completion of treatment, treatment satisfaction, and short- and long-term effectiveness of the treatment.
  4. 4.To examine cost effectiveness of treatment delivery to trauma survivors with PTSD.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Mar 2011

Longer than P75 for phase_3

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2011

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

May 11, 2012

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 17, 2012

Completed
4.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2017

Completed
Last Updated

August 3, 2021

Status Verified

August 1, 2021

Enrollment Period

5.8 years

First QC Date

May 11, 2012

Last Update Submit

August 2, 2021

Conditions

Keywords

PTSDAntidepressantsCognitive behavior therapy

Outcome Measures

Primary Outcomes (1)

  • Posttraumatic stress disorder (PTSD) Symptoms

    Interview measure to assess PTSD symptoms.

    Measured up to 9 months.

Secondary Outcomes (1)

  • Depression symptoms

    Measured up to 9 months.

Study Arms (4)

Choice: Prolonged exposure (PE)

ACTIVE COMPARATOR

Participants randomized to "choice" who choose prolonged exposure (PE).

Behavioral: Prolonged exposure (PE)

Choice: PE plus sertraline

ACTIVE COMPARATOR

Participants randomized to "choice" who choose PE plus sertraline.

Behavioral: Prolonged exposure (PE)Other: PE plus Sertraline

No choice: Prolonged exposure (PE)

ACTIVE COMPARATOR

Participants randomized to "no choice" who are then randomized to PE.

Behavioral: Prolonged exposure (PE)

No Choice: PE plus sertraline

ACTIVE COMPARATOR

Participants randomized to "no choice" who are then randomized to PE plus sertraline.

Behavioral: Prolonged exposure (PE)Other: PE plus Sertraline

Interventions

PE will include 10 weekly sessions of individual cognitive behavioral therapy.

Choice: PE plus sertralineChoice: Prolonged exposure (PE)No Choice: PE plus sertralineNo choice: Prolonged exposure (PE)

PE plus sertraline will include 10 weeks of prolonged exposure therapy plus sertraline. The sertraline dose will be up to 200 mg daily for 10 weeks. There will also be frequent meetings with study psychiatrist. PE will be provided 1x weekly for 10 weeks.

Also known as: Zoloft
Choice: PE plus sertralineNo Choice: PE plus sertraline

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • DSM-IV (Diagnostic \& Statistical Manual of Mental Disorders) diagnosis of PTSD (with severity threshold)
  • Experienced traumatic event at least 12 weeks prior to study entry
  • Willingness to discontinue current CBT or antidepressant treatment if needed

You may not qualify if:

  • Current diagnosis of schizophrenia or delusional disorder
  • Medically unstable bipolar disorder, depression with psychotic features, or depression requiring immediate psychiatric treatment
  • No clear trauma memory or trauma before age 3
  • Current diagnosis of alcohol or substance dependence within 3 months prior to study entry
  • Ongoing intimate relationship with the perpetrator of the traumatic event
  • History of nonresponse to adequate trial of either CBT or sertraline
  • Medical contraindication for sertraline
  • Current high dose use of benzodiazepines
  • Pregnant or sexually active female without adequate birth control

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Psychological Sciences Department Case Western Reserve University

Cleveland, Ohio, 44106, United States

Location

Psychology Department of University of Washington

Seattle, Washington, 98195, United States

Location

Related Publications (3)

  • Rosencrans PL, Walker RSW, Coyne AE, Baier AL, Klein AB, Shekhtman K, Bowling AR, Feeny NC, Zoellner LA. Reciprocal relationships between posttraumatic stress disorder symptoms and positive and negative affect in evidence-based treatments for posttraumatic stress disorder. J Consult Clin Psychol. 2024 Sep;92(9):630-640. doi: 10.1037/ccp0000898.

  • Coyne AE, Mattson E, Bagley JM, Klein AB, Shekhtman K, Payat S, Levine DS, Feeny NC, Zoellner LA. Within-patient association between emotion regulation and outcome in prolonged exposure for posttraumatic stress disorder. J Consult Clin Psychol. 2024 Sep;92(9):582-593. doi: 10.1037/ccp0000837. Epub 2023 Nov 16.

  • Rosencrans PL, Zoellner LA, Feeny NC. A network approach to posttraumatic stress disorder: Comparing interview and self-report networks. Psychol Trauma. 2024 Feb;16(2):340-346. doi: 10.1037/tra0001151. Epub 2021 Oct 21.

Related Links

MeSH Terms

Conditions

Stress Disorders, Post-Traumatic

Interventions

Sertraline

Condition Hierarchy (Ancestors)

Stress Disorders, TraumaticTrauma and Stressor Related DisordersMental Disorders

Intervention Hierarchy (Ancestors)

1-NaphthylamineAminesOrganic ChemicalsNaphthalenesPolycyclic Aromatic HydrocarbonsHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsPolycyclic Compounds

Study Officials

  • Norah C Feeny, PhD

    Case Western Reserve University

    PRINCIPAL INVESTIGATOR
  • Lori A Zoellner, PhD

    University of Washington

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

May 11, 2012

First Posted

May 17, 2012

Study Start

March 1, 2011

Primary Completion

January 1, 2017

Study Completion

January 1, 2017

Last Updated

August 3, 2021

Record last verified: 2021-08

Locations